Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.
Osteoporos Int
; 26(2): 601-10, 2015 Feb.
Article
in En
| MEDLINE
| ID: mdl-25270396
ABSTRACT
SUMMARY:
In patients with systemic lupus erythematosus (SLE), low bone mineral density (BMD) is associated with increased age, prolonged disease, low body mass index (BMI), and overlap with rheumatoid arthritis (RA). Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.INTRODUCTION:
The objective of this study was to investigate the steroid and CsA effect on bone metabolism and serum FGF-23 in SLE patients.METHODS:
Seventy-two SLE patients and 10 age- and sex-matched healthy individuals underwent blood tests for bone metabolic biomarkers and FGF-23, and lumbar spine dual-energy X-ray absorptiometry for BMD.RESULTS:
Comparisons between patients and controls were made in premenopausal women/men younger than 50 years and postmenopausal women/men older than 50 years separately. SLE patients had more frequent low Z-score (≤-2.0, 8.5 vs. 0%), osteopenia (-2.5CONCLUSION:
SLE patients treated with glucocorticoid and CsA exhibited markedly decreased bone turnover. Those taking CsA had higher serum FGF-23 associated with suppression of 1,25(OH)2D3 and bone formation. Such high-risk patients necessitate regular screening of osteoporosis.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cyclosporine
/
Bone Remodeling
/
Fibroblast Growth Factors
/
Glucocorticoids
/
Immunosuppressive Agents
/
Lupus Erythematosus, Systemic
Type of study:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Osteoporos Int
Journal subject:
METABOLISMO
/
ORTOPEDIA
Year:
2015
Document type:
Article
Affiliation country:
Taiwán